Mironid
PrivateLast Round
Series B
Aug 5, 2026
Total Funding Raised
$90.55M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Mironid is a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mironid Comparables
Compare Mironid with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Renasant Bio | 80% | |
| Novartis | 76% | |
| xCystence Bio | 76% |
Mironid Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 5, 2026 | ||||
| Series A Extension | Sep 13, 2023 | ||||
| Series A | Jun 20, 2016 |
Mironid Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Roche Venture Fund | Series B, Series A Extension, Series A |
| Epidarex Capital | Series B, Series A Extension, Series A |
| European Investment Fund | Series A Extension, Series A |
| Scottish National Investment Bank | Series B |
| Sofinnova Partners | Series B, Series A Extension, Series A |
| University of Strathclyde | Series B, Series A Extension, Series A |
| BioGeneration Ventures | Series B, Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 5, 2026
$46M round with participation from BioGeneration Ventures and Epidarex Capital.
- Jun 19, 2026
Monthly visitors increased 58% MoM.
Recent news
Latest coverage and updates
- receives_financingAug 17, 2026
Mironid received financing of $64.1M in Series B on Aug 1st '26.
- is_developingAug 14, 2026
Mironid is developing small molecule therapeutics targeting cyclic AMP on Jul 1st '15.
- is_developingAug 5, 2026
Mironid is developing treatment approach that could improve options for people living with kidney disease.
- receives_financingAug 5, 2026
Mironid received financing of $46M in Series B on Aug 5th '26.
Mironid Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Mironid's valuation, stock price, and market status.
Is Mironid a public or private company?
Mironid is a private company.
What is the current stock price of Mironid?
Mironid is a private company with no public stock price. No recent secondary market data is available.
How much is Mironid worth (valuation)?
Valuation information for Mironid is not publicly available.
Can I buy Mironid stock?
Mironid shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Mironid's last funding round?
Mironid's most recent funding round was Series A on June 20, 2016.
Who are the main investors in Mironid?
Key investors in Mironid include Roche Venture Fund, Epidarex Capital.
Will Mironid IPO soon?
No public IPO plans have been announced for Mironid.
How can I track Mironid secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Mironid's secondary market activity and sign up for updates.